b.jansen
TL2 Moderator · Faro
Contributes reviews on supplier material. Based in Faro.
Joined 13 May 2025 · last posted 20h
73Posts here
2Topics
1Solutions
1.6kLikes received
2kLikes given
24Badges
243Days visited
4.6kPosts read
Recent activity
Full stream-
Review: a draft on reconstitution arithmetic, with objections — one year on Replied, post #52 · Documentation › Doc review · 27 Jul 2026 · 26 likes Review of promoted topics: when a topic is nominated for promotion to a maintained documentation page, the draft is posted here. Community review happens before…
-
Review: an evidence digest and the citation check that delayed it Replied, post #18 · Documentation › Doc review · 26 Jul 2026 · 17 likes This follows post #15 rather than contradicting it. Review date disputes: if a maintained page's review date is approaching and it has not been updated, post a note so…
-
Submitting a sample: the process end to end Replied, post #110 · Sourcing › Independent verification · 25 Jul 2026 · 0 likes PeptideMeter: purity analysis plus structured, dated supplier verification records. Produces both individual analytical results and verification records assessed over…
-
Tracking a shortage from primary sources rather than rumour Replied, post #118 · Access › Shortages · 23 Jul 2026 · 5 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Muscle cramps: the ordinary causes before the exotic ones — a second dataset Replied, post #66 · Practice › Side effects · 22 Jul 2026 · 23 likes Coming back to post #64, because the follow-up matters more than the original answer. Lean mass loss: the rate of lean tissue loss depends on protein intake, resistance…
-
Impurity thresholds: where the common numbers come from Replied, post #6 · Analytics › Impurities & related substances · 16 Jul 2026 · 6 likes This follows post #3 rather than contradicting it. Incomplete deprotection: mass higher by the protecting group mass. Usually markedly later eluting. A synthesis…
-
Restarting after a long gap: what the labelling implies Replied, post #25 · Practice › Dosing & titration · 14 Jul 2026 · 7 likes Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #26 · Access › Insurance & coverage · 14 Jul 2026 · 24 likes Generic versus brand: most of these compounds do not have generic versions yet. Once they do, formulary coverage and pricing will shift.
-
Revisiting: Can a home kit substitute for a laboratory report? A careful no Replied, post #49 · Analytics › Home & field testing · 12 Jul 2026 · 18 likes False positives and false negatives: no test has 100% sensitivity and 100% specificity. A negative result does not guarantee absence; a positive result does not…
-
Coming back to: Time to steady state after a dose increase Replied, post #95 · Pharmacology › Pharmacokinetics · 7 Jul 2026 · 22 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #63 · Access › International · 7 Jul 2026 · 9 likes Coming back to post #61, because the follow-up matters more than the original answer. Licensed prescribing: where a compound is approved, prescribing is restricted to…
-
Second pass at: Cost versus information: making the trade-off explicitly Replied, post #13 · Analytics › Home & field testing · 29 Jun 2026 · 0 likes Worth separating two things that post #9 runs together. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did…